ADA 2016:载脂蛋白B偏高的孕妇应警惕后代心血管风险

2016-06-13 Seven L 译 MedSci原创

据美国糖尿病协会科学会议的数据显示,目前的载脂蛋白B升高,那么其后代将有六倍的可能性也是载脂蛋白B(Apo B)升高。布宜诺斯艾利斯杜兰医院的研究者Valeria Hirschler博士和同事对84名儿童(男孩占42名,平均年龄5.3岁)母亲(平均年龄33.8岁)进行了研究。检测了参与者的BMI、腰围、血脂水平、Apo B、Apo A等指标。数据显示,儿童中有24.4%的为超重,11.5%的为肥胖

据美国糖尿病协会科学会议的数据显示,目前的载脂蛋白B升高,那么其后代将有六倍的可能性也是载脂蛋白B(Apo B)升高。

布宜诺斯艾利斯杜兰医院的研究者Valeria Hirschler博士和同事对84对儿童(男孩占42名,平均年龄5.3岁)和母亲(平均年龄33.8岁)进行了研究。检测了参与者的BMI、腰围、血脂水平、Apo B、Apo A等指标。

数据显示,儿童中有24.4%的为超重,11.5%的为肥胖;母亲里则有39.1%的为超重,以及39.1%的肥胖。当Apo B水平高于第三个四分位77.6mg/dl时,定义为高Apo B水平。

与Apo B水平第三四分位数的母亲的孩子相比,具有高Apo B水平的母亲的儿童有显着较高的BMI z评分 (0.4 vs. 1.2)、腰围(55cm vs. 58cm)、低密度脂蛋白胆固醇(LDL-C)(79mg/dl vs. 98mg/dl)与Apo B水平(73.9 mg/dL vs. 92.5 mg/dL)。

校正年龄、性别和BMI后,具有高Apo B水平的母亲的儿童发生高Apo B水平的OR=5.7(95% CI, 1.3-25.5)。

研究者认为,目前对心血管疾病的风险检测和临床发现具有较长的滞后,如果通过母亲的Apo B水平评估后代情况,就有可能更早的为后代提供干预,降低风险。

原始出处:

Hirschler V, et al. 1277-P. Presented at: American Diabetes Association Scientific Sessions; June 10-14, 2016; New Orleans.

High maternal apolipoprotein B may indicate increased CV risk in children.Healio.June 12, 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691549, encodeId=4dec1691549d7, content=<a href='/topic/show?id=29ba9365035' target=_blank style='color:#2F92EE;'>#载脂蛋白B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93650, encryptionId=29ba9365035, topicName=载脂蛋白B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed8829226564, createdName=liubm565, createdTime=Tue Jan 17 04:13:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082377, encodeId=493420823e77b, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 04 06:13:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264575, encodeId=a3d112645e533, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361280, encodeId=5702136128059, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424651, encodeId=3cd614246515f, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691549, encodeId=4dec1691549d7, content=<a href='/topic/show?id=29ba9365035' target=_blank style='color:#2F92EE;'>#载脂蛋白B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93650, encryptionId=29ba9365035, topicName=载脂蛋白B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed8829226564, createdName=liubm565, createdTime=Tue Jan 17 04:13:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082377, encodeId=493420823e77b, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 04 06:13:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264575, encodeId=a3d112645e533, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361280, encodeId=5702136128059, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424651, encodeId=3cd614246515f, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691549, encodeId=4dec1691549d7, content=<a href='/topic/show?id=29ba9365035' target=_blank style='color:#2F92EE;'>#载脂蛋白B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93650, encryptionId=29ba9365035, topicName=载脂蛋白B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed8829226564, createdName=liubm565, createdTime=Tue Jan 17 04:13:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082377, encodeId=493420823e77b, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 04 06:13:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264575, encodeId=a3d112645e533, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361280, encodeId=5702136128059, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424651, encodeId=3cd614246515f, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
    2016-06-15 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=1691549, encodeId=4dec1691549d7, content=<a href='/topic/show?id=29ba9365035' target=_blank style='color:#2F92EE;'>#载脂蛋白B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93650, encryptionId=29ba9365035, topicName=载脂蛋白B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed8829226564, createdName=liubm565, createdTime=Tue Jan 17 04:13:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082377, encodeId=493420823e77b, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 04 06:13:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264575, encodeId=a3d112645e533, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361280, encodeId=5702136128059, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424651, encodeId=3cd614246515f, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1691549, encodeId=4dec1691549d7, content=<a href='/topic/show?id=29ba9365035' target=_blank style='color:#2F92EE;'>#载脂蛋白B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93650, encryptionId=29ba9365035, topicName=载脂蛋白B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed8829226564, createdName=liubm565, createdTime=Tue Jan 17 04:13:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082377, encodeId=493420823e77b, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 04 06:13:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264575, encodeId=a3d112645e533, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361280, encodeId=5702136128059, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424651, encodeId=3cd614246515f, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Jun 15 05:13:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]

相关资讯

Clinical Nutrition:食用大麦可降低机体胆固醇水平

众所周知,机体需要适当的胆固醇以调节机体代谢。然而高水平的脂肪会增加机体出现心血管疾病包括心脏病和卒中的风险。高胆固醇通常是不健康生活方式所致,提早采取预防措施如健康饮食和规律体育锻炼并采取药物治疗会降低民众出现心血管疾病的风险。研究发表在Clinical Nutrition。大豆食品、坚果、燕麦、大麦以及水果和蔬菜都被认为是可降低机体胆固醇的食物。现在越来越多的证据表明大麦有益于心脏健康。加拿大

ApoB-48可用于诊断早期动脉粥样硬化

  日本学者的一项研究表明,在血压和甘油三酯(TG)处于正常水平的中年人群中,血清载脂蛋白B-48(ApoB-48)可能是诊断早期动脉粥样硬化的适宜标志物。论文于2011年6月6日在线发表于《动脉粥样硬化》(Atherosclerosis)杂志。   餐后高脂血症(PPHL)是心血管疾病的独立危险因素,其病变基础为含apoB-48乳糜微粒(CM)和CM残粒的蓄积。鉴于动脉粥样硬化性心血管疾病在血

NLA 2016:降低ApoC-III可减少心血管风险

国家脂质协会科学会议上的演讲称,遗传和其他证据表明,载脂蛋白C-III的升高是冠心病的危险因素,降低其水平可减少心血管事件的风险。丹麦哥本哈根大学医院临床生物化学和分子心脏病学教授、哥本哈根大学医院医学与健康科学学院教授Anne Tybjaerg-Hansen博士在演讲中说:“对载脂蛋白C-III经过47年的研究之后,对这个物质有了更进一步的认识。”先前的遗传研究已经确定,APOC3基因功能丧失的

J Intern Med:apoA-IV与肾脏功能那些事

载脂蛋白A-IV(apoA-IV)是一种能抗动脉硬化、抗氧化的糖蛋白。目前对于该标志物的研究发现,血浆apoA-IV水平升高主要见于慢性肾脏疾病(CKD)或肾功能衰竭患者。而在普通人群中关于apoA-IV和肾功能之间关系的研究还很少见,因此,研究者就该问题对两项以人群为基础的队列研究进行了相关数据采集和分析。该研究包括KORA F3 共计3159名研究对象,以及KORA F4共计3061名研究对象

Apo等因素与RA患者颈动脉粥样硬化独立相关

来源:医学论坛网   瑞典一项研究表明,载脂蛋白和抗磷酰胆碱(PC)抗体可能在类风湿关节炎(RA)患者发生亚临床动脉粥样硬化中发挥独立作用。该研究论文7月9日在线发表在《风湿病学》(Rheumatology)杂志。   该研究共纳入115例近期发生RA(症状发作后<12个月)患者,年龄平均50.6±11.2岁,68.4%女性,并在RA确诊后评估患者基线、3、12、24和60个月的病情。研究在同